ASND: Ascendis Pharma A/S - ADR Company Profile & Statistics

About

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark.

Info & Links

CEO

Jan M�ller Mikkelsen

Headquarters

TUBORG BOULEVARD 12
HELLERUP, G7 2900, DENMARK

Auditor

Deloitte Statsautoriseret Revisionspartnerselskab

Share holders

Employees

1,017

Ascendis Pharma A/S - ADR Statistics

Valuation Measures

Market Capitalization²

9.26B

Enterprise Value

9.58B

Enterprise Value/EBITDA(ttm)

-33.93

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

24.00

Price to Book(mrq)

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

83.22%

Operating Margin(ttm)

-104.54%

Profit Margin(ttm)

-158.35%

Return on Equity(ttm)

Return on Invested Capital(ttm)

1584.06%

Return on Assets(ttm)

-39.23%

Income Statement

Revenue(ttm)

393.50M

Revenue Per Share(ttm)

6.48

Gross Profit(ttm)

345.60M

EBITDA(ttm)³

-282.48M

Net Income Available to Common(ttm)

-409.12M

Diluted EPS(ttm)

-7.10

Share Statistics

Beta (5Y Monthly)

0.64

52-Week Change

-2.29%

S&P 500 52-Week Change

18.16%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

60.69M

Dividend Yield

0.00%

Float⁴

36.41M

% Held by Insiders

40.00%

% Held by Institutions

Balance Sheet

Total Cash(mrq)

605.48M

Total Cash Per Share(mrq)

9.98

Total Debt(mrq)

926.94M

Total Debt/Equity(mrq)

-810.38%

Current Ratio(mrq)

1.17%

Quick Ratio(mrq)

0.84%

Book Value Per Share(mrq)

-1.88

Cash Flow

Operating Cash Flow Per Share(ytd)

-5.72

Free Cash Flow(ytd)

-331.85M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

ASND

Ascendis Pharma A/S - ADR

Ascendis Pharma A/S - ADR Profile